Six Million Records, 64 Percent Lower Opioid Odds, and Why GRADE Still Says Very Low

Why This Paper Matters

The U.S. opioid crisis remains the dominant pain-policy story of the last fifteen years. Provisional Centers for Disease Control and Prevention data continue to put annual overdose deaths at over 80,000, with prescription opioids contributing as both a primary driver and a known risk factor for transition to illicit use. Spine pain (low back, neck, and mid-back complaints) is the single most common pain indication for which opioids have historically been prescribed. The CDC Clinical Practice Guideline for Prescribing Opioids for Pain (Dowell et al., 2022, MMWR) recommends maximizing nonpharmacologic and nonopioid approaches before reaching for an opioid prescription for most chronic pain conditions.

The unanswered question for both clinicians and policymakers has been the size of the population-scale effect of nonpharmacologic care on actual prescribing patterns. Several earlier studies (Whedon et al., 2018, JMPT; Corcoran et al., 2020) found that patients who use chiropractic care receive opioids at lower rates than matched patients who do not. The samples were measured in tens of thousands at most, and the systematic-review picture of the question stayed thin.

Emary and colleagues set out to fix that gap by pooling everything that has been published. The combined dataset, 6,036,058 patients, is the largest synthesis on this question to date. Whether it definitively answers the question is a separate matter from whether it is the most relevant policy-grade evidence currently available. It is both the largest and the most cautious read of the field.

What the Study Did

The review was conducted by a team led by Peter C. Emary at the Michael G. DeGroote Institute for Pain Research and Care at McMaster University, with co-authors spanning the Veterans Affairs Connecticut Healthcare System, Yale, and other chiropractic outcomes research groups. The authorship roster carries weight in chiropractic outcomes research and in the broader spine-pain evidence space.

The protocol was registered with PROSPERO before data extraction. The team searched MEDLINE, Embase, CINAHL, the Cochrane Central Register of Controlled Trials, ICL, and Web of Science. Eligible studies were randomized controlled trials, prospective cohort studies, retrospective cohort studies, and large claims- or registry-based analyses comparing opioid use outcomes between adults with noncancer spine pain who received chiropractic care and those who did not.

Twenty studies met inclusion. The vast majority were observational, drawing on insurance claims databases, military health system data, Medicare or Medicaid populations, and integrated health-system electronic health records. Pooling was performed using random-effects meta-analysis. Heterogeneity was characterized with the I-squared statistic. Risk of bias was assessed using design-appropriate tools (Cochrane RoB-2 for the small number of randomized trials, ROBINS-I for nonrandomized comparative designs). Certainty of evidence across outcomes was rated using the GRADE framework. Reporting followed PRISMA 2020.

The methodological scaffolding is appropriate. The review is doing what a contemporary systematic review of observational pain-care data should do, with explicit recognition of the limits of the underlying evidence base.

What the Study Found

The headline result is the pooled odds ratio for receiving an opioid prescription. Patients who used chiropractic care for noncancer spine pain had pooled odds of receiving an opioid prescription of approximately 0.36 compared with comparator patients who did not, with a corresponding interpretation of roughly a 64 percent reduction in odds. The point estimate was reasonably consistent across geographic settings, payer types, and design subtypes within the observational pool.

The absolute-numbers picture follows the headline. With more than six million patients pooled, the effect is not a noisy estimate from underpowered studies. Heterogeneity was meaningful, as expected when combining studies with different opioid-prescribing baselines, different chiropractic-utilization definitions, and different time horizons. The direction of the effect did not flip across studies. No included study found that chiropractic care was associated with higher opioid use.

Secondary outcomes (where reported) followed the same direction. Lower morphine milligram equivalent doses among those who did receive opioids. Shorter durations of opioid therapy. Lower rates of long-term opioid use (defined variably across studies as 60 to 90 days or more of continuous prescribing). Each of these secondary findings rests on smaller subsets of the pooled data and carries wider confidence intervals.

The certainty rating, applied across every outcome the review evaluated, came out as very low per GRADE. That is the rating any honest reader has to carry into the interpretation. A very-low rating does not mean the finding is wrong. It means the design of the available evidence does not support strong claims about the size of the causal effect, and that future high-quality research could meaningfully shift the estimate.

Mechanism and Clinical Context

Why would chiropractic care be associated with lower opioid prescribing for noncancer spine pain? The mechanistic answer is both simple and partial.

For mechanical low back pain, chiropractic care delivers spinal manipulation, soft-tissue work, mobilization, and graded loading that act on the local mechanical contributors to pain (joint restriction, surrounding muscle tone, movement patterning). The Cochrane de Zoete 2026 update pooled 76 RCTs on spinal manipulation for chronic low back pain and found small-to-medium effects on pain at low certainty, with no signal of serious adverse events. The Bronfort 2026 PACBACK trial in JAMA tested manipulation against medical care and against biopsychosocial self-management, finding that biopsychosocial self-management beat usual medical care while manipulation alone did not consistently outperform medical care on the primary outcome. The clinical signal across this body of work is modest pain benefit, similar to or better than non-opioid medical management.

Mechanistically, when patients reach pain levels they consider tolerable through non-pharmacological means, the demand for opioid prescriptions drops. The intervention does not have to "cure" the spine pain to reduce opioid demand. It has to reduce pain and improve function enough that the patient and clinician do not escalate to opioids as the next step.

There is also a referral-pathway story. Patients who present to a chiropractor first are entering a care pathway that does not have opioid prescribing as a default option. A patient who presents to a primary-care office or an urgent care for the same complaint is in a pathway where an opioid is on the menu. The Emary review cannot separate the pain-relief mechanism from the pathway-of-care mechanism. Both probably contribute to the observed association.

None of this proves causation. It explains why an association of this size would be biologically and structurally plausible. Mechanism plausibility is necessary, not sufficient, for causal claims.

Limitations and Caveats

The very-low GRADE rating is not a footnote. It is the central honest reading of this paper. Several specific issues drive that rating, and they are worth naming.

The methodological problems above are not unique to this review. They are characteristic of the entire body of population-scale evidence on nonpharmacologic care and opioid prescribing. The Emary team's contribution is to pool the largest dataset ever assembled on this question and to honestly grade the certainty as very low. That second part matters as much as the first.

What I Take From This for Practice

I see noncancer spine pain every day in my Tulsa walk-in clinic. The typical case is a working-age adult presenting with mechanical low back pain, mid-back tightness, or cervicogenic headache, often after weeks of self-management failed and before they have considered going to a primary care provider. The clinical question I am most often answering is not "should this patient get an opioid." It is "what is the next reasonable step in this patient's care."

The Emary review does not change my fundamental approach to that patient. What it does is sharpen the language I can use when patients ask about the bigger pain-and-medication picture. I now have a defensible citation for the statement that chiropractic utilization is associated with substantially lower opioid prescribing in adults with noncancer spine pain. The honest qualifier travels with the citation: this association is consistent across a six-million-patient dataset, with very low certainty about the size of the true causal effect.

For clinical practice, I take three concrete things from this paper.

One: The pathway-of-care framing is worth taking seriously.

If part of the observed association is driven by patients entering a care pathway without opioid-as-default, then the public-health value of widening access to nonpharmacologic care is partly about which pathway patients enter, not just about which intervention they receive once they are in it. That has implications beyond what individual chiropractors do in their own clinics. It is a referral-architecture and insurance-design question.

Two: The conservative-first care pathway has consistent evidence behind it, even when each individual piece is graded low or very low.

Cochrane gave spinal manipulation for chronic LBP a small-to-medium effect at low certainty (de Zoete 2026). PACBACK showed biopsychosocial self-management beat usual medical care at the trial level (Bronfort 2026). The Emary review now adds population-scale evidence consistent with both. None of these papers alone is decisive. Read together, they triangulate the same direction. That is how cumulative evidence builds in pain research, even when the GRADE ratings stay modest.

Three: The very-low certainty rating cuts against overclaiming, but it does not cut against the recommendation.

A patient or a referring clinician who asks "is the evidence strong" should hear "no, the certainty is very low." A patient or referring clinician who asks "is the evidence consistent" should hear "yes, the direction of effect across 6 million patient records is consistent." Both statements are true. Conflating them is the failure mode the GRADE framework was built to prevent.

The CDC Clinical Practice Guideline already recommends nonpharmacologic approaches as first-line care for many forms of chronic noncancer pain. The Emary review is consistent with that recommendation. It does not constitute the high-certainty causal evidence that would let the guideline upgrade the recommendation strength. A different study design, ideally large pragmatic trials embedded in real-world health systems, would be required for that.

What I tell patients in my Tulsa walk-in clinic when they ask about the medication picture has not fundamentally changed. Conservative care first, with a clear plan for when to escalate or refer. Imaging when red flags are present. Honest discussion of what chiropractic does well (mechanical pain modulation, function restoration, return to load tolerance) and what it does not do well (centrally-mediated pain, certain neuropathic patterns, conditions outside scope of practice). The Emary review supports that conversation. It does not change its content.

What the Review Does Not Resolve

The review does not establish that chiropractic care causes lower opioid use. The data is not designed to support that claim. A pragmatic randomized trial of "first-line chiropractic referral" versus "usual care" with opioid prescribing as the primary outcome would. No such trial currently exists at the scale this question requires.

The review does not separate by spine-pain subtype. Acute low back pain, chronic low back pain, neck pain, mid-back pain, and radicular pain are all mechanically and prognostically distinct. The pooled estimate treats noncancer spine pain as a single category. Subgroup analysis by pain duration and anatomical region would clarify which patient subsets show the largest signal.

The review does not test the chiropractic-utilization-intensity relationship. Whether one chiropractic visit is associated with the same odds reduction as a course of ten visits is a separate question that the pooled data does not answer cleanly.

The review does not adjudicate which specific chiropractic interventions drive the association. Spinal manipulation, manual therapy, exercise prescription, education, and lifestyle counseling are all delivered in chiropractic care, in varying combinations. The Emary pool treats "chiropractic care" as the unit of comparison. It does not unpack that unit.

None of these unresolved questions undermine the headline. They define the next research agenda.